To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet’s disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433–0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.

Fabiani, C., Vitale, A., Rigante, D., Emmi, G., Lopalco, G., Sota, J., et al. (2018). Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. CLINICAL RHEUMATOLOGY, 37(6), 1715-1720 [10.1007/s10067-018-4092-4].

Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab

Vitale, Antonio;Sota, Jurgen;Franceschini, Rossella;Capozzoli, Marco;Frediani, Bruno;Galeazzi, Mauro;Tosi, Gian Marco;Cantarini, Luca
2018-01-01

Abstract

To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet’s disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433–0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
2018
Fabiani, C., Vitale, A., Rigante, D., Emmi, G., Lopalco, G., Sota, J., et al. (2018). Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. CLINICAL RHEUMATOLOGY, 37(6), 1715-1720 [10.1007/s10067-018-4092-4].
File in questo prodotto:
File Dimensione Formato  
Predictors-Of-Sustained-Clinical-Response-Fabiani-2018.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 400.44 kB
Formato Adobe PDF
400.44 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1057968